Pfizer Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Albert Bourla
- Full Time Employees
- 75,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 66 Hudson Boulevard East New York City NY United States of America 10001-2192
- IPO Date
- Jun 1, 1972
- CIK
- 0000078003
- Website
- pfizer.com
- Similar Companies
- Business
- Pfizer Inc. (NYSE: PFE) develops, manufactures, and markets biopharmaceutical products worldwide, focusing on oncology, vaccines, internal medicine, inflammation and immunology, and rare diseases. The company offers a broad portfolio including oncology drugs such as Ibrance (palbociclib), Xtandi (enzalutamide), Padcev (enfortumab vedotin), Elrexfio (elranatamab), Bosulif (bosutinib), Braftovi (encorafenib), Lorbrena (lorlatinib), Talzenna (talazoparib), and Tivdak (tisotumab vedotin); vaccines like Comirnaty (COVID-19 mRNA vaccine), Prevnar 13/20 (pneumococcal conjugate vaccines), Abrysvo (RSV vaccine), and Penbraya (meningococcal vaccine); cardiovascular and metabolic treatments including Eliquis (apixaban), Vyndaqel/Vyndamax (tafamidis), and Norvasc (amlodipine); primary care products such as Zavzpret (zavegepant), Chantix (varenicline), and Litfulo (ritlecitinib); antivirals like Paxlovid (nirmatrelvir/ritonavir); and consumer brands including Advil, ChapStick, and Robitussin. Founded in 1849 by Charles Pfizer and Charles F. Erhart and headquartered at 235 East 42nd Street in Manhattan, New York City, Pfizer operates manufacturing and research facilities globally across North America, Europe, Asia, and Latin America, serving healthcare providers, governments, and patients in over 100 countries. In recent developments, Pfizer completed the acquisition of Metsera in November 2025 for an initial enterprise value of $4.9 billion plus a contingent value right, adding clinical-stage obesity and cardiometabolic candidates including oral and injectable incretins; new products and acquired launches contributed $7.3 billion in incremental revenue through Q3 2025; and the company plans $10-15 billion in business development investments for 2025, emphasizing early-stage assets and collaborations, particularly with Chinese biotechs via its Ignite platform.
Company News
Here's What $10,000 in Each of These 5 High-Yield Dividend Stocks Could Pay You in a Year
Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe?
Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady
Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
6 Blue Chip Stocks Trading Well Below Their Highs
Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Pfizer, Thermo Fisher Scientific And More: CNBC's ‘Final Trades'
Pfizer Inc. (PFE) – What Are Researchers Thinking About This Stock?
Pfizer (PFE) Gains As Market Dips: What You Should Know
Morningstar’s Dividend ETF Is Kind of Perfect for Retirees Right Now
How to Build $9,050 a Month in Dividend Income Without Selling a Single Share
5 Large-Cap Giants Paying 5% and Bigger Dividends to Be Bought and Held Forever
Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
Johnson & Johnson Drops 5% as One-Time Charges Overshadow Raised Full-Year Outlook; Eli Lilly Dips, Pfizer Sits Out the Selloff
FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban
A $750,000 Roth IRA Portfolio Loaded With These Dividend Stocks Pays $47,800 a Year and the IRS Gets None of It
Pfizer: The Earnings Test That Matters
These 6 Dividend Stocks Look Like Income Bargains. Their Payout Ratios Say Otherwise
Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules